Literature DB >> 15958130

Harmful effects of anti-GalNAc-GD1a antibodies and TNF-alpha on rat dorsal root ganglia.

Keiko Kamakura1, Ken-ichi Kaida, Susumu Kusunoki, Norikazu Miyamoto, Toshihiro Masaki, Ryohji Nakamura, Kazuo Motoyoshi, Jun Fukuda.   

Abstract

The clinical characteristics of five (22%) of 23 patients with Guillain-Barré syndrome (GBS), whose serum contained immunoglobulin G (IgG) antibodies to the ganglioside N-acetylgalactosaminyl GD1a (GalNAc-GD1a), included pure motor weakness of the axonal type. These patients had a relatively good prognosis, but displayed higher serum tumor necrosis factor-alpha (TNF-alpha) titers than the other GBS patients. We examined the effect of serum from these patients with IgG anti-GalNAc-GD1a antibodies on neurites from cultured rat dorsal root ganglia (DRG) and found it to damage the myelin in well-elongated DRG neurites and monolayer cultures of Schwann cells and neurons. In the regeneration model, serum from these patients delayed neurite extension and inhibited Schwann cell proliferation. Neurons in cultured monolayers showed vacuolation and decreased rapidly in number. Schwann cells were also vacuolated and readily detached from the substratum. The effects of IgG anti-GalNAc-GD1a antibodies purified from one of the patients, rabbit serum after immunization with GalNAc-GD1a, and recombinant TNF-alpha were also examined. IgG anti-GalNAc-GD1a antibodies mainly inhibited the regeneration and preservation of neurons, while TNF-alpha mainly induced morphological changes in well-proliferated Schwann cells and myelin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958130     DOI: 10.1111/j.1085-9489.2005.0010209.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  4 in total

1.  Myelin-Associated Glycoprotein Inhibits Schwann Cell Migration and Induces Their Death.

Authors:  Nagarathnamma Chaudhry; Corinne Bachelin; Violetta Zujovic; Melissa Hilaire; Katherine T Baldwin; Rose M Follis; Roman Giger; Bruce D Carter; Anne Baron-Van Evercooren; Marie T Filbin
Journal:  J Neurosci       Date:  2017-05-18       Impact factor: 6.167

2.  Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants.

Authors:  Michiaki Koga; Masaki Takahashi; Keiko Yokoyama; Takashi Kanda
Journal:  J Neurol       Date:  2015-06-09       Impact factor: 4.849

3.  The Pathogenesis of the Demyelinating Form of Guillain-Barre Syndrome (GBS): Proteo-peptidomic and Immunological Profiling of Physiological Fluids.

Authors:  Rustam H Ziganshin; Olga M Ivanova; Yakov A Lomakin; Alexey A Belogurov; Sergey I Kovalchuk; Igor V Azarkin; Georgij P Arapidi; Nikolay A Anikanov; Victoria O Shender; Mikhail A Piradov; Natalia A Suponeva; Anna A Vorobyeva; Alexander G Gabibov; Vadim T Ivanov; Vadim M Govorun
Journal:  Mol Cell Proteomics       Date:  2016-05-03       Impact factor: 5.911

Review 4.  Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review.

Authors:  Bonifacio Alvarez-Lario; Rosa Prieto-Tejedo; María Colazo-Burlato; Jesús Macarrón-Vicente
Journal:  Clin Rheumatol       Date:  2013-05-11       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.